Rezolute (RZLT) Cash from Investing Activities (2012 - 2026)
Rezolute (RZLT) posted Cash from Investing Activities of $12.3 million for Q1 2026, down 46.17% sequentially from $22.8 million in Q4 2025, and down 46.73% YoY from $23.1 million in Q1 2025.
Analysis
Rezolute (RZLT) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Rezolute has reported Cash from Investing Activities for 13 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 46.73% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.0 million (down 792.0% YoY) and the FY2025 annual result came in at -$14.5 million, down 129.86% from the prior year.
- Cash from Investing Activities declined to $12.3 million in Q1 2026 per RZLT's latest filing, from $22.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $23.1 million in Q1 2025 and troughed at -$95.0 million in Q1 2023.
- A 5-year average of -$6.7 million and a median of $2.6 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 21497.59% in 2023, then sank 1996.01% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$83000.0 in 2022, then jumped by 21497.59% to $17.8 million in 2023, then sank by 35.42% to $11.5 million in 2024, then soared by 98.92% to $22.8 million in 2025, then sank by 46.17% to $12.3 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $12.3 million, $22.8 million, and -$68.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | 12.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 12.28 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | -68.49 Mn |
| Jun 30, 2025 | 346,000.00 |
| Mar 31, 2025 | 23.05 Mn |
| Dec 31, 2024 | 11.47 Mn |
| Sep 30, 2024 | -49.41 Mn |
| Jun 30, 2024 | 19.66 Mn |
| Mar 31, 2024 | 8.67 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Sep 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -94.95 Mn |
| Dec 31, 2022 | -83,000.00 |
| Sep 30, 2022 | -70,000.00 |
| Jun 30, 2019 | -6,000.00 |
| Mar 31, 2019 | 41,861.00 |
| Dec 31, 2018 | 8,000.00 |
| Sep 30, 2018 | 187,139.00 |
| Jun 30, 2018 | 1.55 Mn |